← 10x Genomics, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($18.8m) | ($112.5m) | ($31.3m) | ($542.7m) | ($58.2m) | ($166.0m) | ($255.1m) | ($182.6m) | ($43.5m) | — | |
| Depreciation and amortization | $4.3m | $3.9m | $7.1m | $14.0m | $21.1m | $25.4m | $35.5m | $35.9m | $36.2m | $47.9m | |
| Amortization of right-of-use assets | — | $0 | $0 | $5.0m | $7.1m | $7.6m | $8.1m | $7.8m | $7.6m | — | |
| Stock-based compensation expense | $1.7m | $2.7m | $13.3m | $48.6m | $96.0m | $136.8m | $166.9m | $140.7m | $109.1m | $98.7m | |
| Asset and lease impairment charges | — | — | — | — | — | — | $9.8m | $3.1m | $814k | — | |
| ROU assets impairment due to restructuring | — | — | — | — | — | — | $0 | $0 | $1.3m | — | |
| Accounts receivable | ($5.1m) | ($14.7m) | ($5.3m) | ($17.8m) | ($34.0m) | ($18.9m) | ($10.6m) | $27.0m | $41.3m | $68.6m | |
| Other receivables | — | — | — | — | — | — | $0 | $0 | ($34.9m) | — | |
| Inventory | ($2.0m) | ($3.7m) | ($6.7m) | ($14.6m) | ($30.1m) | ($21.2m) | $7.9m | ($9.8m) | $28.0m | $18.6m | |
| Accounts payable | $3.0m | $2.6m | $4.9m | ($7.8m) | $11.1m | $5.9m | ($6.0m) | ($3.4m) | ($2.1m) | $2.5m | |
| Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities | $250k | $2.3m | $4.5m | $3.0m | $17.0m | $26.8m | $3.3m | $1.4m | $215k | ($5.6m) | |
| Accrued compensation and other related benefits | $3.5m | $2.6m | $5.3m | $2.9m | $16.3m | $1.1m | ($2.6m) | $3.7m | $7.6m | — | |
| Deferred revenue | $1.3m | $1.7m | $634k | $2.0m | $1.5m | $3.4m | $10.9m | $11.2m | $746k | — | |
| Accrued expenses and other current liabilities | $1.8m | $1.7m | $5.8m | $25.9m | ($873k) | $3.3m | $28.3m | ($12.7m) | ($5.2m) | — | |
| Other | — | — | — | — | $79k | $2.0m | $427k | $523k | ($1.8m) | — | |
| Prepaid expenses and other current assets | ($702k) | ($2.4m) | ($3.5m) | ($5.3m) | ($1.1m) | ($4.5m) | ($2.4m) | ($1.9m) | ($2.3m) | — | |
| Net cash provided by (used in) operating activities | ($10.7m) |
($76.4m)
-614.17%
|
$34.6m
+145.32%
|
($217.9m)
-729.27%
|
($21.4m)
+90.19%
|
($33.6m)
-57.24%
|
($15.2m)
+54.78%
|
$6.7m
+143.85%
|
$136.1m
+1941.57%
|
$127.1m
-6.59%
|
|
| Purchases of property and equipment | ($3.8m) | ($6.3m) | ($42.7m) | ($36.7m) | ($101.3m) | ($131.7m) | ($48.6m) | ($12.4m) | ($5.9m) | ($5.6m) | |
| Realized loss on marketable securities | — | — | — | — | $0 | $0 | $1.7m | $3k | $0 | — | |
| Proceeds from maturities of marketable securities | — | — | — | $0 | $0 | $18.5m | $82.8m | $25.8m | $125.2m | — | |
| Proceeds from sales of marketable securities | — | — | — | $0 | $0 | $49.1m | $100.2m | $3.9m | $0 | — | |
| Purchase of marketable securities | — | — | — | $0 | $0 | ($282.9m) | $0 | ($48.9m) | ($123.4m) | — | |
| Net cash (used in) provided by investing activities | ($3.8m) | ($6.7m) | ($42.8m) | ($38.4m) | ($106.7m) | ($350.9m) | $133.5m | ($32.6m) | ($13.4m) | — | |
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | — | $1.8m | $3.8m | $23.7m | $40.3m | $21.2m | $19.5m | $10.9m | $6.8m | $0 | |
| Common stock issued for acquisition of assets | — | — | — | — | — | — | $0 | $0 | $13.5m | — | |
| Net cash provided by financing activities | $20.6m |
$105.4m
+411.91%
|
$414.6m
+293.47%
|
$468.9m
+13.10%
|
$35.3m
-92.47%
|
$15.8m
-55.19%
|
$13.7m
-13.58%
|
$10.9m
-20.16%
|
$6.8m
-37.67%
|
($2.5m)
-137.37%
|
|
| Net increase (decrease) in cash and cash equivalents | $6.1m | $22.2m | $406.4m | $212.2m | ($92.6m) | ($368.7m) | $131.9m | ($15.2m) | $129.9m | — | |
| Cash, cash equivalents and restricted cash at beginning of year | $47.9m | $70.1m | $476.5m | $688.6m | $596.1m | $227.4m | $359.3m | $344.1m | $474.0m | — | |
| Effect of exchange rate changes on cash and cash equivalents | ($14k) | ($18k) | ($45k) | ($463k) | $234k | ($44k) | ($33k) | ($164k) | $484k | ($91k) | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Fair value adjustments on contingent consideration | — | — | — | — | — | — | $0 | $0 | $1.4m | — | |
| Other noncurrent assets | $33k | ($999k) | ($251k) | ($2.7m) | $1.0m | $925k | ($678k) | ($1.1m) | $689k | — | |
| Operating lease liability | — | $0 | $0 | ($4.8m) | ($2.5m) | ($6.4m) | ($8.7m) | ($12.5m) | ($10.3m) | — | |
| Other noncurrent liabilities | $118k | $33k | $547k | ($3.8m) | ($4.7m) | ($2.9m) | $1.3m | $776k | $1.4m | — | |
| Asset acquisition, net | — | — | — | — | — | — | $0 | $0 | ($9.3m) | — | |
| Purchase of intangible assets | — | ($425k) | ($25k) | ($1.7m) | $0 | $0 | ($923k) | ($1.0m) | $0 | — | |
| Payments on technology license financing arrangement | — | $0 | $0 | ($5.8m) | ($5.0m) | ($5.4m) | ($5.8m) | $0 | $0 | — | |
| Cash paid for interest | $658k | $1.8m | $2.2m | $1.7m | $1.2m | $841k | $436k | $0 | $0 | — | |
| Cash paid for taxes | — | $6k | $22k | $280k | $8.7m | $3.9m | $4.9m | $5.6m | $2.4m | — | |
| Right-of-use assets obtained in exchange for new operating lease liabilities | — | $0 | $0 | $13.6m | $21.3m | $16.6m | $6.5m | $0 | $11.4m | — |